Clinical Trial: A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease

U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07551492) titled 'A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease' on April 17.

Brief Summary: The purpose of the study is to evaluate the impact of HRS9531 on major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease. This study adopts an event-driven design and ends when the target number of the primary endpoint event is reached.

Study Start Date: May, 2026

Study Type: INTERVENTIONAL

Condition: Atherosclerotic Cardiovascular Disease

Intervention: DRUG: HRS9531

HRS9531 Dose 1 , subcutaneous injection

DRUG: HRS9531 placebo

H...